Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

Supportive Care in Cancer

Volumn 17, Issue 12, 2009, Pages 1483-1491

  Shimozuma, Kojiro ^a   Ohashi, Yasuo ^b   Takeuchi, Ayano ^b   Aranishi, Toshihiko ^b   Morita, Satoshi ^c   Kuroi, Katsumasa ^d   Ohsumi, Shozo ^e   Makino, Haruhiko ^f   Mukai, Hirohumi ^g   Katsumata, Noriyuki ^h   Sunada, Yoshihide ⁱ   Watanabe, Toru ^j   Hausheer, Frederick H ^k  

^a RITSUMEIKAN UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f NIIGATA CITY GENERAL HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁱ KAWASAKI MEDICAL SCHOOL   (Japan)

^j Hamamatsu Oncology Center   (Japan)

^k BioNumerik Pharmaceuticals Inc   (United States)

more..

Author keywords

Neurotoxicity; Patient Neurotoxicity Questionnaire (PNQ) Validation; Patient reported outcomes; Peripheral neuropathy

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PATIENT NEUROTOXICITY QUESTIONNAIRE; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VALIDITY;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEASIBILITY STUDIES; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PATIENT COMPLIANCE; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TAXOIDS;

EID: 71349087162     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0613-7     Document Type: Article

References (29)

1. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JCJM de Haes S Kaasa M Klee D Osoba D Razavi PB Rofe S Schraub K Sneeuw M Sullivan F Takeda European Organization for Research and Treatment of Cancer Study Group on Quality of Life 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 365 376 10.1093/jnci/85.5.365 10.1093/jnci/85.5.365 1:STN:280: DyaK3s7msVarsQ%3D%3D 8433390
2. JA Ajani SR Welch MN Raber WS Fields IH Krakoff 1990 Comprehensive criteria for assessing therapy-induced toxicity Cancer Invest 8 147 159 10.3109/07357909009017560 10.3109/07357909009017560 1:STN:280: DyaK3czotFGltg%3D%3D 2400936
3. E Basch A Lasonos T McDonough A Barz A Culkin MG Kris HI Scher D Schrag 2006 Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study Lancet Oncol 7 903 909 10.1016/S1470-2045(06) 70910-X 10.1016/S1470-2045(06)70910-X 17081915
4. MM Boehmke SS Dickerson 2005 Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities Cancer Nurs 28 382 389 10.1097/00002820-200509000-00008 10.1097/00002820-200509000-00008 16192830 (Pubitemid 41395659)
5. AE Bonomi DF Cella EA Hahn K Bjordai B Sperner-Unterweger L Gangeri B Bergman J Willems-Groot P Hanquet R Zittoun 1996 Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system Qual Life Res 5 309 320 10.1007/BF00433915 10.1007/BF00433915 1:STN:280:DyaK28zitFOltA%3D%3D 8763799 (Pubitemid 26228464)
6. EA Calhoun EE Welshman CH Chang JR Lurain DA Fishman TL Hunt D Cella 2003 Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy Int J Gynecol Cancer 13 741 748 10.1111/j.1525-1438.2003.13603.x 10.1111/j.1525-1438.2003.13603.x 1:STN:280:DC%2BD3srpsVCjsw%3D%3D 14675309 (Pubitemid 38235217)
7. DF Cella DS Tulsky G Gray B Sarafian E Linn A Bonomi M Silberman SB Yellen P Winicour J Brannon K Eckberg S Lioyd S Purl C Blendowski M Goodman M Barnicle I Stewart M McHale P Bonomi E Kaplan TS IV CR Thomas Jr J Harris 1993 The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure J Clin Oncol 11 570 579 1:STN:280:DyaK3s7oslKqsQ%3D%3D 8445433
8. J Cohen 1968 Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit Psychol Bull 70 213 220 10.1037/h0026256 10.1037/h0026256 1:STN:280:DC%2BD1MrltVyrtA%3D%3D 19673146
9. Fayers PM, Machin D (2007) Scores and measurements: validity, reliability, sensitivity. Quality of life: the assessment, analysis, and interpretation of patient-reported outcomes, 2nd edn. Wiley, Chichester, pp 77-107
10. EK Fromme KM Eilers M Mori Y-C Hsieh TM Beer 2004 How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30 J Clin Oncol 22 3485 3490 10.1200/JCO.2004.03.025 10.1200/JCO.2004.03.025 15337796 (Pubitemid 41103654)
11. H Fumimoto K Kobayashi C-H Chang S Eremenco Y Fujiki S Uemura Y Ohashi S Kudoh 2001 Cross-cultural validation of an international questionnaire, the General Measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese Qual Life Res 10 701 709 10.1023/A:1013851216181 10.1023/A:1013851216181 1:STN:280:DC%2BD387js12lsw%3D%3D 11871591 (Pubitemid 34145321)
12. FH Hausheer RL Schilsky S Bain EJ Berghorn F Lieberman 2006 Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy Semin Oncol 33 15 49 10.1053/j.seminoncol.2005.12.010 10.1053/j.seminoncol.2005.12.010 1:CAS:528:DC%2BD28XisFCjur0%3D 16473643 (Pubitemid 43214485)
13. HQ Huang MF Brady D Cella G Fleming 2007 Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a Gynecologic Oncology Group study Int J Gynecol Cancer 17 387 393 10.1111/j.1525-1438.2007.00794.x 10.1111/j.1525-1438.2007.00794.x 1:STN:280:DC%2BD2s7mtF2gsg%3D%3D 17362317 (Pubitemid 46426765)
14. RA Hughes 2002 Peripheral neuropathy BMJ 324 466 469 10.1136/bmj.324. 7335.466 10.1136/bmj.324.7335.466 11859051
15. M Kurihara H Shimizu K Tsuboi K Kobayashi M Murakami K Eguchi K Shimozuma 1999 Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy Psychooncology 8 355 363 10.1002/(SICI) 1099-1611(199907/08) 8:4<355::AID-PON401>3.0.CO;2-I 10.1002/(SICI)1099-1611(199907/08)8:4<355::AID-PON401>3.0.CO;2-I 1:STN:280:DyaK1MvgsVWjsw%3D%3D 10474853
16. K Kuroi K Shimozuma 2004 Neurotoxicity of the taxanes: symptoms and quality of life assessment Breast Cancer 11 92 99 10.1007/BF02968010 10.1007/BF02968010 14718800
17. JR Landis GG Koch 1977 The measurement of observer agreement for categorical data Biometrics 33 159 174 10.2307/2529310 10.2307/2529310 1:STN:280:DyaE2s7jsFWqtA%3D%3D 843571
18. J Lipscomb BB Reeve SB Clauser JS Abrams DW Bruner LB Burke AM Denicoff PA Ganz K Gondek LM Minasian AM O'Mara DA Revicki EP Rock JH Rowland M Sgambati EL Trimble 2007 Patient-reported outcomes assessment in cancer trials: taking stock, moving forward J Clin Oncol 25 5133 5140 10.1200/JCO.2007.12.4644 10.1200/JCO.2007.12.4644 17991933 (Pubitemid 350232295)
19. Mamounas EP, Bryant J, Lembersky BC, Fisher B, Atkins JN, Fehrenbacher L, Raich PC, Yothers G, Soran A, Wolmark N; NSABP Operations and Biostatistical Center, Pittsburgh, PA (2003) Paclitaxel (T) following doxorubicin/ cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 22. Abstract 12.
20. S Ohsumi Y Sunada 2004 Techniques for the neurological examination of taxane-induced neuropathy Breast Cancer 11 86 91 10.1007/BF02968009 10.1007/BF02968009 14718799
21. MA Petersen H Larsen L Pedersen N Sonne M Groenvold 2006 Assessing health-related quality of life in palliative care: comparing patient and physician assessments Eur J Cancer 42 1159 1166 10.1016/j.ejca.2006.01.032 10.1016/j.ejca.2006.01.032 16624553
22. TJ Postma NK Aaronson JJ Heimans MJ Muller JG Hildebrand JY Delattre K Hoang-Xuan M Lantéri-Minet R Grant R Huddart C Moynihan J Maher R Lucey EORTC Quality of Life Group 2005 The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20 Eur J Cancer 41 1135 1139 10.1016/j.ejca.2005.02.012 10.1016/j.ejca.2005.02.012 1:STN:280:DC%2BD2M3mvVOmsQ%3D%3D 15911236 (Pubitemid 40725571)
23. TJ Postma JJ Heimans 2000 Grading of chemotherapy-induced peripheral neuropathy Ann Oncol 11 509 513 10.1023/A:1008345613594 10.1023/A:1008345613594 1:STN:280:DC%2BD3M%2Fms1OhsQ%3D%3D 10907941 (Pubitemid 30431370)
24. TJ Postma JJ Heimans MJ Muller GJ Ossenkoppele JB Vermorken NK Aaronson 1998 Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy Ann Oncol 9 739 744 10.1023/A:1008344507482 10.1023/A:1008344507482 1:STN:280:DyaK1cvhtFOmtQ%3D%3D 9739440 (Pubitemid 28394160)
25. S Quasthoff HP Hartung 2002 Chemotherapy-induced peripheral neuropathy J Neurol 249 9 17 10.1007/PL00007853 10.1007/PL00007853 1:CAS:528: DC%2BD38XisVKkt7k%3D 11954874
26. JA Sloan L Berk J Roscoe MJ Fisch EG Shaw G Wyatt GR Morrow AC Dueck 2007 Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-Sponsored Clinical Trials Networks J Clin Oncol 25 5070 5077 10.1200/JCO.2007.12.7670 10.1200/JCO.2007.12. 7670 17991923 (Pubitemid 350232285)
27. C Spearman 1904 The proof and measurement of association between two things Am J Psychol 15 72 101 10.2307/1412159 10.2307/1412159
28. RJ Stephens P Hopwood DJ Girling D Machin 1997 Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 6 225 236 10.1023/A:1026458604826 10.1023/A:1026458604826 1:STN:280:DyaK2szntVKqtg%3D%3D 9226980
29. AJ Windebank W Grisold 2008 Chemotherapy-induced neuropathy J Peripher Nerv Syst 13 27 46 10.1111/j.1529-8027.2008.00156.x 10.1111/j.1529-8027.2008. 00156.x 1:CAS:528:DC%2BD1cXltl2ktrc%3D 18346229